[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100340829":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":22,"centralContacts":23,"locations":33,"responsibleParty":49,"collaborators":51,"id":55,"slug":56,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":61,"eligibilityCriteria":62,"healthyVolunteers":57,"sex":63,"minAge":64,"maxAge":22,"enrollmentInfo":65,"targetDuration":22,"studyType":68,"phases":69,"briefSummary":71,"conditions":72,"keywords":22,"overallStatus":35,"whyStopped":22,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},{"fullName":5,"class":6},"Melbourne Health","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Posaconazole prophylaxis","EXPERIMENTAL","Blood samples will be taken from participants undergoing cancer treatment and receiving Posaconazole prophylaxis. The samples will be used for Posaconazole pharmacokinetics study.",[13],"Drug: Posaconazole pharmacokinetics",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Posaconazole pharmacokinetics","Blood samples will be collected on Days 7, 14 and 21 from the onset of Posaconazole prophylactic treatment If significant diarrhoea occurs, additional blood samples will be collected twice weekly until symptoms resolve. All blood samples will be used for Posaconazole pharmacokinetics study.",[9],[21],"Blood sampling",null,[24,29],{"name":25,"role":26,"phone":27,"phoneExt":22,"email":28},"Monica Slavin, Prof","CONTACT","61 3 9342 9403","monica.slavin@mh.org.au",{"name":30,"role":26,"phone":31,"phoneExt":22,"email":32},"Tseng Lau, PhD","61 3 9342 8274","tseng.lau@mh.org.au",[34],{"facility":5,"status":35,"city":36,"state":37,"zip":38,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"RECRUITING","Parkville","Victoria","3050","Australia","AU",{"type":42,"coordinates":43},"Point",[44,45],144.95,-37.78333,{"lat":45,"lon":44},[48],{"name":30,"role":26,"phone":22,"phoneExt":22,"email":22},{"type":50,"investigatorFullName":22,"investigatorTitle":22,"investigatorAffiliation":22,"oldNameTitle":22,"oldOrganization":22},"SPONSOR",[52],{"name":53,"class":54},"Merck Sharp & Dohme LLC","INDUSTRY","100340829","phase-4-posaconazole-pharmacokinetics-in-patients-receiving-chemotherapy-or-stem-cell-transplants-100340829",false,"NCT03717623","Posaconazole Pharmacokinetics in Patients Receiving Chemotherapy or Stem Cell Transplants","Pharmacokinetics Study of Posaconazole in Haematology Patients Receiving Standard of Care Treatment With Oral Posaconazole Prophylaxis for Invasive Fungal Infection","POPULAR","Inclusion Criteria:\n\n* Adult (≥18 years old) haematology patients receiving Posaconazole prophylaxis in the inpatient setting as standard of care.\n* Able to give informed consent.\n\nExclusion Criteria:\n\n* Unable to give informed consent.","ALL","18 Years",{"count":66,"type":67},100,"ESTIMATED","INTERVENTIONAL",[70],"PHASE4","The purpose of the study is to investigate the pharmacokinetics of oral dosage of Posaconazole which is routinely administered as a standard care prophylaxis for patients undergoing cancer treatments.",[73,74,75,76,77,78,79],"Posaconazole","Pharmacokinetics","Invasive Candidiases","Invasive Aspergillosis","Invasive Mycosis","Fungal Infection","Prophylaxis","2025-02-26",{"date":82,"type":83},"2025-02-28","ACTUAL",{"date":85,"type":83},"2019-08-01",{"date":87,"type":67},"2025-12-30",{"name":5,"class":6},1]